Neuroprotection by Acetyl-L-Carnitine after Traumatic Injury to the Immature Rat BrainScafidi S.a · Racz J.b, c · Hazelton J.b, c · McKenna M.C.a · Fiskum G.b, c
Departments of aPediatrics and bAnesthesiology, and cCenter for Shock, Trauma, and Anesthesiology Research, University of Maryland School of Medicine, Baltimore, Md., USA Corresponding Author
Dr. Gary Fiskum
Department of Anesthesiology, University of Maryland School of Medicine
685 West Baltimore Street
Baltimore, MD 21201 (USA)
Tel. +1 410 706 4711, Fax +1 410 706 2550, E-Mail firstname.lastname@example.org
Traumatic brain injury (TBI) is the leading cause of mortality and morbidity in children and is characterized by reduced aerobic cerebral energy metabolism early after injury, possibly due to impaired activity of the pyruvate dehydrogenase complex. Exogenous acetyl-L-carnitine (ALCAR) is metabolized in the brain to acetyl coenzyme A and subsequently enters the tricarboxylic acid cycle. ALCAR administration is neuroprotective in animal models of cerebral ischemia and spinal cord injury, but has not been tested for TBI. This study tested the hypothesis that treatment with ALCAR during the first 24 h following TBI in immature rats improves neurologic outcome and reduces cortical lesion volume. Postnatal day 21–22 male rats were isoflurane anesthetized and used in a controlled cortical impact model of TBI to the left parietal cortex. At 1, 4, 12 and 23 h after injury, rats received ALCAR (100 mg/kg, intraperitoneally) or drug vehicle (normal saline). On days 3–7 after surgery, behavior was assessed using beam walking and novel object recognition tests. On day 7, rats were transcardially perfused and brains were harvested for histological assessment of cortical lesion volume, using stereology. Injured animals displayed a significant increase in foot slips compared to sham-operated rats (6 ± 1 SEM vs. 2 ± 0.2 on day 3 after trauma; n = 7; p < 0.05). The ALCAR-treated rats were not different from shams and had fewer foot slips compared to vehicle-treated animals (2 ± 0.4; n = 7; p< 0.05). The frequency of investigating a novel object for saline-treated TBI animals was reduced compared to shams (45 ± 5% vs. 65 ± 10%; n = 7; p < 0.05), whereas the frequency of investigation for TBI rats treated with ALCAR was not significantly different from that of shams but significantly higher than that of saline-treated TBI rats (68 ± 7; p < 0.05). The left parietal cortical lesion volume, expressed as a percentage of the volume of tissue in the right hemisphere, was significantly smaller in ALCAR-treated than in vehicle-treated TBI rats (14 ± 5% vs. 28 ± 6%; p < 0.05). We conclude that treatment with ALCAR during the first 24 h after TBI improves behavioral outcomes and reduces brain lesion volume in immature rats within the first 7 days after injury.
© 2011 S. Karger AG, Basel
Traumatic injury to the adult and developing brain is characterized by impairment of cerebral energy metabolism within minutes to hours after the initial injury and therefore prior to most of the subsequent cell death [1,2]. The molecular basis for the reduced aerobic energy metabolism and associated increase in glycolytic lactate production is not completely elucidated [2,3,4]. Oxidative modification and inactivation of one or more mitochondrial metabolic enzymes, and possible impairment of the malate-aspartate shuttle function have been reported . Evidence obtained from animal models of both traumatic brain and spinal cord injury and from ischemia/reperfusion paradigms point towards the pyruvate dehydrogenase complex (PDHC) as a critical metabolic enzyme that is particularly sensitive to inhibition within a few hours after the initial injury, by either oxidative modifications or serine phosphorylation [4,5,6,7,8,9,10,11,12,13,14,15]. Since the overall reaction catalyzed by this complex constitutes the bridge between glycolysis and the first step of the tricarboxylic acid (TCA) cycle, impairment of the aerobic energy metabolism at the level of the PDHC can potentially be overcome by use of alternative fuels that enter the cycle distal to this reaction. Such fuels include ketone bodies, fatty acids and acyl carnitines, which can all be metabolized to form acetyl coenzyme A (CoA), the product of the PDHC reaction and a substrate for the citrate synthase reaction within the TCA cycle [4,16,17,18,19,20,21,22]. Acetyl-L-carnitine (ALCAR) is a naturally occurring metabolic intermediate involved in transmitochondrial membrane trafficking of acetyl units for both catabolic and anabolic metabolism [23,24]. ALCAR can be transported across the cell membrane and the mitochondrial inner membrane by carnitine translocases in exchange for free carnitine . Once inside the mitochondrial matrix, ALCAR is converted to acetyl CoA and free carnitine via carnitine acyl transferases . Numerous reports show neuroprotective effects of exogenous ALCAR in a number of neurologic disorders [22,25,26,27,28,29,30]. Supraphysiologic levels of exogenously administered ALCAR provide neuroprotection in animal models of neurodegenerative diseases and acute neurologic injury paradigms [22,23,24,31]. Posttreatment of adult animals with ALCAR reduces neurologic impairment and/or neuronal death in rodent models of stroke [32,33,34] and in a canine model of cardiac arrest . ALCAR also reduces spinal cord mitochondrial respiratory impairment and reduces gray matter lesion volume in an adult rodent model of spinal cord injury . There are no published studies, however, that have tested neuroprotection by ALCAR in the injured immature brain, where the pathophysiology is significantly different from that of the mature brain [2,35,36,37]. We have recently demonstrated that following systemic administration, the acetyl moiety of 13C-labeled ALCAR is metabolized for energy via the TCA cycle in astrocytes and neurons within the forebrains of 21- to 22-day-old rats . Furthermore, 13C from ALCAR was incorporated into γ-aminobutyric acid (GABA), glutamate and glutamine, which are formed subsequent to TCA cycle metabolism . In light of the ability of the immature rat brain to utilize ALCAR for both energy metabolism and neurotransmitter formation, this study tested the hypothesis that administration of ALCAR after controlled cortical impact (CCI) traumatic brain injury (TBI) to 21- to 22-day-old rats improves neurologic outcome and reduces brain cell death.
All animal procedures were approved by the University of Maryland Animal Care and Use Committee and are in compliance with the National Institutes of Health guidelines. TBI was induced using an established immature rat model . Male Sprague-Dawley rats were weaned from their dams at postnatal day (PND) 20 and used for experiments on PND 21 or 22. The animals were randomly assigned to 4 groups: CCI + vehicle (normal saline); CCI + ALCAR; sham + vehicle, and sham + ALCAR. At 1, 4, 12 and 23 h after surgery, the animals received 100 mg/kg ALCAR or vehicle (normal saline) by intraperitoneal injection. The rats received maintenance anesthesia (2% isoflurane) via nose cone with 30% oxygen. A rectal probe and heating blanket were used to maintain a rectal temperature of 37.0 ± 0.5°C. A left parietal craniotomy was created using a high-speed drill. CCI injury was induced with a 6-mm flat-tipped impactor at a velocity of 5.5 m/s, a depth of 1.5 mm, and a duration of 50 ms. Following the impact, the bone flap was replaced, the craniotomy sealed and the scalp incision closed with sutures. Sham animals were anesthetized and received a craniotomy but no impact. After the surgical procedures had been completed, anesthesia was discontinued.
Beam Walking. The rats were tested for their ability to traverse an inclined (35-degree angle) elevated beam (width: 1 cm; length: 100 cm) during postinjury days 3–7; the data were obtained by recording the traverse time and number of foot slips .
Novel Object Recognition. On day 6 after surgery, animals were habituated in a closed Plexiglas arena (48 cm long, 40 cm wide, 30 cm high) for 1 min as described by Bevins and Besheer , and then returned to their home cage. To minimize anxiety, this arena was placed within a 5 times larger arena with dark walls in a dimly lit room. For the exploration phase, which was conducted 1 h after the habituation phase, 2 identical objects were placed equidistantly into the inner arena across from where the rat was placed. The rats were allowed to investigate for 15 min and explore the objects. Exploration was defined as sniffing and/or touching the objects. The rats were returned to their home cages. On postinjury day 7, 24 h after the exploration phase, the rats were again placed within the arena in the absence of objects for 1 min and then returned to their home cages. For the test phase conducted 1 h later, 1 of the familiar objects was replaced with a novel object and the animals were allowed to explore the arena. Rats have a natural predilection for new items, thus the percent time spent exploring a new object reflects the degree to which they remember the familiar object [41,42].
On day 7 after injury or sham surgery and after completion of the behavioral studies, all animals were perfused with 4% paraformaldehyde and brains were harvested. Brains were removed from the skull and transferred into 30% sucrose. Once the brains had sunk to the bottom of the container, they were cut (35 µm) on a freezing sliding microtome, yielding 24 series per animal, and kept in cryoprotectant (–20°C) until further processing was initiated. Seven sections, 35 µm thick and 840 µm apart, corresponding to the epicenter of the CCI injury, plus 3 sections rostral and 3 sections caudal to the epicenter, were carefully mounted on slides and stained with cresyl violet.
Design-based stereology was performed on the stained sections using a Nikon Eclipse E800 microscope equipped with a MicroBrightField 3-axis, computer-controlled, motorized stage, an Optronics 1-CCD digital video camera and a PC workstation (Intel Core 2 Duo E6850 processor). Quantitative analyses of the entire anterior-posterior extent of the necrotic cortical lesion volume were performed using the Cavalieri method and SterioInvestigator software (MicroBrightField, Wiliston, Vt., USA) by a microscopist blinded to the treatment protocol. For each section analyzed, the Cavalieri estimator probe was utilized to overlay a rectangular lattice of points every 50 µm across the ipsilateral and contralateral cortical areas. The number of points in the lattice that lay within the ipsilateral cortical contusion (tissue lost) and corresponding contralateral section were counted under ×10 magnification. Borders between healthy and necrotic cortex were generally sharp and easily identified because necrotic tissue was either lost or contained very few viable neurons. Neurons with an intact nucleolus and regular distribution of Nissl bodies throughout their cytoplasm were considered viable, while shrunken neurons with a condensed nucleus and lacking a nucleolus were considered nonviable (fig. 4). Cortical regions surrounding the necrotic divot that were devoid of viable cells were included as part of the lesion volume. Because necrotic tissue is frequently lost with processing, the upper border for ipsilateral lesioned cortex was estimated to reflect the upper border of tissue from the corresponding healthy contralateral cortex (dashed lines in figure 4) from the same slice of tissue. A minimum of 250 points were counted per subject to ensure robustness of the data.
Necrotic divot and contralateral cortical areas and volumes were calculated separately by the StereoInvestigator software. The area representing ipsilateral lesioned and contralateral healthy cortex was first calculated per section by multiplying the number of points counted per region by the grid area (g2) associated with each point: A = p·g2. The volume of the necrotic divot and contralateral cortical tissue throughout the anterior-posterior extent of the hemispheres was then estimated by multiplying the sum of areas (ΣA) by the periodicity (m) and the mean section thickness (t): est (V) = (ΣA)mt. Finally, the cortical lesion volume in the ipsilateral cortex is expressed as a percentage of the volume of the entire contralateral cortex volume by the equation: %V = (Vdivot/Vcontra) × 100 .
All data were analyzed using GraphPad prism 5 software. Data from behavioral experiments (beam walking and novel object recognition, NOR) were analyzed using two-way repeated measures analysis of variance (ANOVA) with group (sham or CCI) and treatment (saline or ALCAR) as factors, followed by post hoc testing using the Bonferroni method. Differences in the lesion volumes of CCI + saline and CCI + ALCAR groups were determined using Student’s t test. The level of significance was set at p < 0.05 for all data.
A beam walking test was used to assess the effects of CCI and treatment with ALCAR on the sensorimotor abilities of immature rats. The tests were performed starting at day 3 after CCI or sham surgery and continued for 5 days until day 7 after injury. All groups of sham and injured rats were able to traverse an inclined beam, and there were no significant differences in traverse time between the groups on any of the days studied (fig. 1). The quality of beam walking was assessed by quantifying the number of foot slips, as shown in figure 2. For the foot slip data, a repeated measures two-way ANOVA revealed a group effect [F(12, 220) = 3.92; p < 0.0001], indicating overall differences between the different treatment groups in the study, as well as a treatment effect [F(3, 55) = 24.85; p < 0.0001] and group × treatment interaction [F(12, 220) = 3.92; p < 0.0001], indicating significant performance differences between the treatment groups. Since all the groups studied improved over 5 days of beam walking testing, an additional analysis was performed using group and time as factors. In addition to a group effect, it revealed a time effect [F(4, 220) = 30.87; p < 0.0001], indicating significant overall changes in performance over the duration of the study, and group × day interaction [F(12, 275) = 2.434; p < 0.01], indicating significant performance difference between the groups over time. Post hoc analysis with Bonferroni posttests detected significant differences for days 3–7 between CCI rats treated with saline and both the sham groups and the CCI + ALCAR treatment group (p < 0.001). There were no significant differences between the sham + saline and sham + ALCAR groups. The number of foot slips for CCI rats treated with ALCAR was also not significantly different from either sham-operated group.
The NOR test was used to assess the effects of CCI and treatment with ALCAR on recognition memory. The rats were familiarized with the objects on day 6 after injury and their preference for novel objects was tested on day 7 after injury; the results of these tests are shown in figure 3. Both sham groups exhibited a strong preference for the novel object with 66.8 ± 4.0% (sham + saline) and 65.5 ± 3.5% (sham + ALCAR) of the test period spent exploring the novel object. The percent time that sham rats spent exploring the novel object is comparable to values reported for normal adult and juvenile rats [40,44,45]. The CCI rats treated with ALCAR also exhibited a significant preference for the novel object (67.9 ± 3.9%) and did not differ from either sham group in this respect. In contrast, rats subjected to CCI + saline treatment spent significantly less time exploring the novel object (44.9 ± 3.1%; p < 0.001) than the CCI + ALCAR and the sham groups. The amount of time CCI + saline rats spent exploring the novel object was similar to a random chance performance of 50%. A repeated measures ANOVA yielded a significant group effect [F(1, 24) = 7.17; p = 0.013], indicating overall differences between the treatment groups in the study, as well as a treatment effect [F(1, 24) = 8.96; p < 0.01] and group × treatment interaction [F(1, 24) = 21.77; p < 0.005]. Post hoc analysis using the Bonferroni posttest detected a significant difference (p < 0.001) between the CCI + normal saline group and the other groups studied (sham + normal saline, sham + ALCAR and CCI + ALCAR).
The CCI model resulted in a moderate degree of TBI, defined by extensive unilateral loss of cortical brain tissue without gross damage to underlying structures including the hippocampus . At day 7 after injury, 27.8 ± 4.5% of the total cortical volume in the left (ipsilateral) cerebral hemisphere (compared to the contralateral side) was lost in CCI + saline rats. In contrast, the CCI animals treated with ALCAR had significantly less cortical lesion volume lost (14.5 ± 3.5%) than the CCI + saline group (p < 0.04; t test), as shown in figure 4.
The overall findings of this study are that treatment with ALCAR after moderate TBI in immature rats from CCI reduced both the neurologic impairment and the cortical lesion volume that occurred within 7 days after injury. ALCAR was administered 4 times intraperitoneally at a dose of 100 mg/kg at 1, 4, 12 and 23 h after the CCI . The dosing schedule by Aureli et al.  was used since it led to a complete recovery of brain ATP levels at 2–48 h after injury in a rat stroke model. Previous findings in our laboratory also demonstrated neuroprotection with 100 mg/kg ALCAR in an adult rat stroke model and in an adult canine cardiac arrest model [21,33]. Although the current study is the first study to demonstrate neuroprotection by ALCAR in any TBI model, ALCAR administered intraperitoneally at 300 mg/kg also reduced lesion volume and improved the respiration of isolated mitochondria in a rat spinal cord injury model . No study has examined dose-response relationships, thus it remains unknown whether greater neuroprotection would be observed in the rat CCI model with doses higher than 100 mg/kg or whether lower doses would also be effective. The present study and the two other studies employing rat models all used 2 or more doses of ALCAR [6,33,46], whereas the canine study employed 1 early intravenous bolus administration . It is not known how many doses of ALCAR are optimal for neuroprotection after TBI. Importantly, all of the rodent studies demonstrated neuroprotection by ALCAR treatment administered 1 h after injury, which is the clinically relevant time of treatment for human TBI. As the safety profile of ALCAR is extremely good [47,48], it could be readily translated for use in clinical trials.
The finding that significant improvement was observed in two discrete behavioral tests supports the conclusion that ALCAR is neuroprotective after TBI. Beam walking is a well-established method to assess sensorimotor function in rats and mice , and is used to assess impairment after cortical focal [49,50,51] and global  injury. This method is widely used in assessing neurologic insult and/or recovery after TBI . The number of foot slips on the beam walking test was significantly higher in the CCI + saline rats compared to the sham groups. This finding is consistent with other studies that reported increased numbers of foot slips in injured rodents following brain trauma [49,51]. Our results show that treatment with ALCAR during the first 24 h after CCI led to improved neurologic outcome, as determined by a significantly decreased number of foot slips compared to the CCI + saline group. Appelberg et al.  reported that feeding a ketogenic diet after CCI injury to juvenile rats led to improved beam walking performance and spatial memory.
The performance of all animal groups in our study improved over time, as has been reported by other investigators . The mechanism of this motor improvement is not completely understood . One possibility is that motor recovery is regulated by modulating cerebellar input since isolated direct cerebellar injury results in impaired beam walking [52,53,54]. In the present study, no differences were detected in the time required to traverse the beam, consistent with reports from other groups that TBI injury did not affect traverse time for beam walking in juvenile (PND 35) and adult rats (PND 75) .
Hippocampal neuronal death typically accompanies the overlying cortical lesion in the rat CCI model of TBI . Although the hippocampus remains anatomically intact, secondary injury to the hippocampus leads to impaired function, which can be assessed by behavioral tasks including learning and recognition memory . The NOR test, which involves memory of a familiar object as well as detection and encoding of a novel object, has been extensively used to study cognitive function in rodents . It is particularly useful for studying memory in immature rodents since object recognition is well studied in many species including humans . At day 7 after TBI, the rats were 28–29 days old and developmentally capable of exhibiting novel object preference up to 24 h after familiarization . In our experiments, TBI caused significant impairment of NOR 7 days after TBI; however, this deficit was not observed in the CCI rats treated with ALCAR during the first 24 h after TBI. In addition to improving neurologic outcome, treatment with ALCAR after injury significantly reduced the cortical lesion volume 7 days after CCI. The lesion volume in CCI + ALCAR rats was approximately 50% smaller than the lesion volume in the CCI + saline rats. Lesion volume is a highly objective outcome measure, based on the rigorous and unbiased stereologic approach used. Future experiments will determine the efficacy of ALCAR in sparing selective neuronal death in the penumbral hippocampal region. Although Prins et al.  reported that a ketogenic diet decreased the lesion volume by 58% in 35-day-old rats 7 days after TBI, treatment with the ketogenic diet had no effect on the 17-day-old rats tested.
The primary limitation of this study is that only short-term behavioral and histologic results were obtained. Future studies will be necessary to determine if treatment with ALCAR also improves long-term neurologic outcome and reduces cortical lesions and delayed cell death in the penumbra several months after injury. Another limitation is that only male animals were used, and therefore the results cannot be extrapolated to females.
The mechanism of neuroprotection by ALCAR is not well understood. Based on what is known about the biochemical mechanisms of secondary injury due to TBI and the neurochemical effects of ALCAR, it is likely that ALCAR provides neuroprotection by improving cerebral energy metabolism and, therefore, lessens the chance of necrotic cell death caused by metabolic failure. Indeed, Patel et al.  demonstrated that treatment with ALCAR ameliorated mitochondrial dysfunction after contusion spinal cord injury. Since cerebral oxidative glucose metabolism is impaired after TBI in the immature brain , at several levels including the PDHC, alternate fuels that can bring substrates directly to the TCA cycle (after the block at the PDHC) are likely to provide therapeutic benefit. Our group and others have shown that the maximal activity and/or immunoreactivity of PDHC subunits is reduced within the first few hours after both global cerebral ischemia and TBI [5,6,7,8,10,11,12,13,14]. ALCAR can supply acetyl CoA as a substrate for brain energy metabolism, and can both improve brain ATP levels and decrease brain lactate after injury [21,30,46]. Furthermore, administration of 3-hydroxybutyrate, another substrate that enters the metabolism at the level of acetyl CoA, improves ATP production after TBI in adult rats .
Our group recently demonstrated that [2-13C]ALCAR (with 13C present in the acetyl moiety) is utilized for energy and neurotransmitter synthesis in the brains of normal, 21- to 22-day-old rats . The formation of 13C-labeled glutamate, glutamine and GABA, which are all metabolites generated from TCA cycle intermediates, demonstrated for the first time that exogenously administered ALCAR is used by the brain for energy metabolism . Future studies will determine if the oxidative metabolism of 13C-labeled ALCAR in the brain is increased after TBI, relative to the metabolism observed in sham rats. The high rate of metabolism of ALCAR via the pyruvate recycling pathway in the immature brain may provide additional neuroprotection . Other possible mechanisms of neuroprotection by ALCAR include the use of the acetyl moiety for synthesis of the inhibitory neurotransmitter GABA , general anti-inflammatory actions of exogenously administered carnitine , the reduction of oxidative stress [30,59,60,61,62,63,64,65] and the ability of ALCAR to activate the Nrf2 pathway of inducing antioxidant gene expression [26,27,66]. The possibility that there are multiple mechanisms responsible for neuroprotection by ALCAR supports its use in additional preclinical studies and for potential clinical trials.
The study was supported by NIH grant No. P01HD16596 and by a grant from the University of Maryland Departmet of Pediatrics.
Dr. Gary Fiskum
Department of Anesthesiology, University of Maryland School of Medicine
685 West Baltimore Street
Baltimore, MD 21201 (USA)
Tel. +1 410 706 4711, Fax +1 410 706 2550, E-Mail email@example.com
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.